logo
ResearchBunny Logo
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

Medicine and Health

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

H. Kim, H. Xu, et al.

This groundbreaking study reveals that ovarian cancer resistant to PARP inhibitors can be effectively targeted with ATR inhibitors, demonstrating improved survival rates in patient-derived xenograft models. Conducted by renowned researchers including Hyoung Kim, Haineng Xu, and Fiona Simpkins, the findings suggest a powerful therapeutic combination for overcoming resistance in ovarian cancer treatment.

00:00
00:00
Playback language: English
Citation Metrics
Citations
0
Influential Citations
0
Reference Count
0

Note: The citation metrics presented here have been sourced from Semantic Scholar and OpenAlex.

Related Publications

Explore these studies to deepen your understanding of the subject.

Open Access Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
Medicine and Health

Open Access Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Y. Harada, A. Sato, et al.

Self-assembly of an anion receptor with metal-dependent kinase inhibition and potent *in vitro* anti-cancer properties
Chemistry

Self-assembly of an anion receptor with metal-dependent kinase inhibition and potent *in vitro* anti-cancer properties

S. J. Allison, J. Bryk, et al.

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
Medicine and Health

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

J. F. E. Mann, P. Rossing, et al.

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial
Medicine and Health

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial

S. Mukherjee, C. N. Hurt, et al.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny